A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Overview
- Phase
- Phase 2
- Intervention
- Atezolizumab
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Sponsor
- NeoImmuneTech
- Enrollment
- 83
- Locations
- 22
- Primary Endpoint
- Objective Response Rate (ORR)
- Status
- Active, Not Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not received prior systemic therapy in the metastatic or locally advanced setting. Eligible subjects must have measurable disease according to RECIST 1.1. This Phase II study will enroll up to 83 subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Have histologically or cytologically confirmed metastatic or locally advanced NSCLC, and have not received prior systemic therapy. Subjects with locally advanced disease must have Stage III NSCLC and are not candidates for surgical resection or definitive chemoradiation
- •Tumor PD-L1 expression (TPS≥1%) as determined by PD-L1 22C3 immunohistochemistry local or central assay.
- •Have measurable disease
- •Agree to provide screening biopsy (or archival tissue) at screening to assess PD-L1
- •Adequate hematologic and end organ function
Exclusion Criteria
- •Prior systemic anti-cancer therapy
- •NSCLC with EGFR, or ALK, or BRAF or ROS or RED or other genomic tumor aberrations which have available therapy
- •Prior radiotherapy within 2 weeks of start of study treatment
- •Known active CNS metastasis or carcinomatous meningitis
- •Severe reactions to mAbs or IV immunoglobulin preparations
- •Autoimmune disease history in past two years
Arms & Interventions
NT-I7 and atezolizumab
Participants with no prior systemic therapy for advanced NSCLC will receive 1200 μg/kg NT-I7 IM on Day 1 and every 6 weeks and atezolizumab IV 1200 mg every 3 weeks until disease progression.
Intervention: Atezolizumab
NT-I7 and atezolizumab
Participants with no prior systemic therapy for advanced NSCLC will receive 1200 μg/kg NT-I7 IM on Day 1 and every 6 weeks and atezolizumab IV 1200 mg every 3 weeks until disease progression.
Intervention: efineptakin alfa
Outcomes
Primary Outcomes
Objective Response Rate (ORR)
Time Frame: approximately 2 years
The percentage of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR), per RECIST 1.1 and iRECIST as determined by the investigator.
Secondary Outcomes
- Duration of response (DoR)(approximately 2 years)
- Overall survival (OS)(approximately 2 years)
- Progression Free Survival (PFS)(approximately 2 years)
- Disease Control Rate (DCR)(approximately 2 years)